(Q40235641)

18 September 2017

EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer (English)

1 reference

18 September 2017

1 reference

3

1 reference

18 September 2017

S H Choi

1

1 reference

18 September 2017

J M Mendrola

series ordinal

2

1 reference

18 September 2017

language of work or name

English

0 references

publication date

4 September 2006

1 reference

18 September 2017

1 reference

18 September 2017

26

1 reference

18 September 2017

11

1 reference

18 September 2017

1567-1576

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1209957

18 September 2017

0 references

cites work

Epidermal growth factor receptor dependence in human tumors: more than just expression?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Transfer of functional EGF receptors to an IL3-dependent cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Epithelioid and fibroblastic rat kidney cell clones: Epidermal growth factor (EGF) receptors and the effect of mouse sarcoma virus transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

The ErbB receptors and their role in cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

On the nature of low- and high-affinity EGF receptors on living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

The cellular response to neuregulins is governed by complex interactions of the erbB receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Local aggregation of hormone–receptor complexes is required for activation by epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Mechanism of biological synergy between cellular Src and epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Signal transduction by receptors with tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

inferred from DOI database lookup

7 January 2021

based on heuristic

Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209957

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.ONC.1209957

1 reference

Dimensions Publication ID

18 September 2017

0 references

1 reference